Hepatitis C Virus (HCV) Protease Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hepatitis C Virus (HCV) Protease Inhibitor The report ...
January 2022
60 pages
Hepcidin Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hepcidin Antagonist The report assesses ...
January 2022
60 pages
HIF-1 Alpha Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “HIF-1 Alpha Inhibitor The report assesses the active HIF-1 Alpha ...
January 2022
60 pages
HIV Attachment Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “HIV Attachment Inhibitor The report assesses ...
January 2022
60 pages
Hypoxia Inducible Factor 1 (HIF-1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hypoxia Inducible Factor 1 (HIF-1) Inhibitor The report ...
January 2022
60 pages
IkappaB Kinase (IKK) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “IkappaB Kinase (IKK) Inhibitor The report assesses ...
January 2022
60 pages
IL-6 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “IL-6 Receptor Antagonist The report assesses ...
January 2022
60 pages
Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitor ...
January 2022
60 pages
Inhibitor of Apoptosis (IAP) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Inhibitor of Apoptosis (IAP) Antagonist The report ...
January 2022
60 pages
Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Insulin Like Growth Factor (IGF) Inhibitor The report ...
January 2022
60 pages
Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Insulin Like Growth Factor 1 (IGF-1) Activators The ...
January 2022
60 pages
Integrase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Integrase Inhibitor The report assesses ...
January 2022
60 pages
Integrin Alpha 4beta1/Very Late Antigen-4 (VLA-4) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Integrin Alpha 4beta1/Very Late Antigen-4 (VLA-4) Inhibitor The ...
January 2022
60 pages
interleukin Agonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “interleukin Agonist The report assesses ...
January 2022
120 pages
Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-1 (IL-1) Inhibitor The report assesses ...
January 2022
120 pages
Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-10 (IL-10) Receptor Agonist The report ...
January 2022
60 pages
Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-12 (IL-12) Inhibitor The report ...
January 2022
60 pages
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-13 (IL-13) Inhibitor The report ...
January 2022
60 pages
Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-17 (IL-17) Inhibitor The report ...
January 2022
60 pages
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-18 (IL-18) Inhibitor The report ...
January 2022
60 pages
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-2 (IL-2) Inhibitor The report assesses ...
January 2022
60 pages
Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-2 (IL-2) Receptor Agonist The report ...
January 2022
60 pages
Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-23 (IL-23) Inhibitor The report ...
January 2022
90 pages
Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-4 (IL-4) Inhibitor The report assesses ...
January 2022
60 pages
Interleukin-5 (IL-5) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-5 (IL-5) Inhibitor The report assesses ...
January 2022
60 pages
Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-8 (IL-8) Inhibitor The report assesses ...
January 2022
60 pages
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ionotropic Glutamate Receptor Antagonist The report ...
January 2022
100 pages
Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Isocitrate Dehydrogenase (IDH1) Inhibitor The report ...
January 2022
60 pages
Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2022
US$ 2,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Janus Kinase (JAK) Inhibitor The report assesses ...
January 2022
150 pages
Mayus Kinase 1 (JAK1) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Janus Kinase 1 (JAK1) Inhibitor The report assesses ...
January 2022
90 pages
Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Janus Kinase 3 (JAK3) Inhibitor The report assesses ...
January 2022
60 pages
Kainate Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kainate Receptor Antagonist The report assesses ...
January 2022
60 pages
Kallikrein Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kallikrein Inhibitor The report assesses ...
January 2022
60 pages
Kappa Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kappa Antagonist The report assesses the active Kappa Antagonist ...
January 2022
60 pages
Kv1.3/1.5 Potassium Channel Blockers - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kv1.3/1.5 Potassium Channel Blockers The report ...
January 2022
60 pages
Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kv1.3 Potassium Channel Blockers The report ...
January 2022
60 pages
LAG-3 Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “LAG-3 Antagonist The report assesses the active LAG-3 Antagonist ...
January 2022
70 pages
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor The ...
January 2022
60 pages
Leukotriene Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Leukotriene Antagonist The report assesses ...
January 2022
60 pages
Leukotriene D4 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Leukotriene D4 Antagonist The report assesses ...
January 2022
60 pages
Lipoxygenase Inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Lipoxygenase Inhibitor (LOX Inhibitor) The report ...
January 2022
80 pages
Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor The ...
January 2022
60 pages
Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Lysine Specific Demethylase 1 (LSD-1) Inhibitor The ...
January 2022
60 pages
Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Matrix Metalloproteinase (MMP) Inhibitor The report ...
January 2022
120 pages
Matrix Metalloproteinase 9 (MMP-9) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Matrix Metalloproteinase 9 (MMP-9) Inhibitor The report ...
January 2022
60 pages
Melanocortin 4 Receptor (MC4R) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Melanocortin 4 Receptor (MC4R) Agonist The report ...
January 2022
60 pages
Metabotropic Glutamate Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Metabotropic Glutamate Receptor Agonist The report ...
January 2022
60 pages
